NEW YORK, February 6 (FinanceEqnuiry.com) - Analysts at Deutsche Bank Securities reiterate their Hold rating on the shares of Edward Lifesciences (NYSE: EW). The 12-month target price is set to $75.
 
In a research note published on February 3, the analysts mention that EW reported weaker than expected 4Q11, due to an operational perspective, though EPS was supported by lower tax rate. The analysts believe that transcatheter valves will be the long term future, while the near term uptake may be beneath the company’s expectations due to lack of visibility in the CRM reimbursement and other competitive dynamics. The analysts reiterate hold rating as EW shares will largely reflect the opportunity with transcatheter valves.